GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 14 Mar 2013.
Bruton agammaglobulinemia tyrosine kinase
Btk, XLA, Bruton's tyrosine kinase, Xid
The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. [provided by RefSeq, Nov 2008] (from
NCBI)
Sponsored links
Papers using
Btk
antibodies
Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors
Supplier
In The Journal of Experimental Medicine, 1997
... Rabbit antisera recognizing the mouse EpoR, PLCγ1, Btk, c-Kit, and the antiphosphotyrosine mouse monoclonal antibody PY99 were obtained from Santa Cruz Biotechnology, Inc ...
The A and the extended V N-terminal regions of streptococcal protein I/IIf mediate the production of tumour necrosis factor alpha in the monocyte cell line THP-1.
Supplier
In PLoS ONE, 1997
... Anti-Btk mouse IgG monoclonal antibodies were from BD Transduction Laboratories (Le Pont de Claix, France) and anti-TNF-α mouse monoclonal antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany) ...
Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ
Supplier
In The Journal of Cell Biology, 1997
... and BtkPH, restriction sites were introduced by PCR using the indicated primers, the Advantage™ II PCR enzyme system (CLONTECH Laboratories, Inc.) and the ...
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.
Supplier
In Respiratory Research, 1993
... Briefly, mononuclear cells were surface stained with phycoerythrin-labeled anti-CD14 antibody, then fixed, permealized, incubated with anti-BTK monoclonal antibody 48-2H [5] or control IgG1 (Dako, Kyoto, Japan), and then ...
Papers on
Btk
Role of Bruton's tyrosine kinase (BTK) in myeloma cell migration and induction of bone disease.
New
United States. In Am J Hematol, 02 Apr 2013
Bruton's tyrosine kinase (BTK), of the TEC family, is expressed in hematopoietic cells and is particularly involved in B-lymphocyte function and osteoclastogenesis.
Emerging drug profiles: Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765).
New
In Leuk Lymphoma, 21 Mar 2013
Abstract Over the past 3 years, ibrutinib (PCI-32765) has emerged as a breakthrough in targeted therapy for patients with certain types of B cell malignancies.
Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM)-mediated Inhibitory Signaling is Regulated by Sequential Phosphorylation Mediated by Distinct Nonreceptor Tyrosine Kinases: A Case Study Involving PECAM-1.
New
In Biochemistry, 18 Mar 2013
NRTKs capable of mediating the second phosphorylation event include C-terminal Src kinase (Csk) and Bruton's tyrosine kinase (Btk).
Targeting the SYK-BTK Axis for the Treatment of Immunological and Hematological Disorders Recent Progress and Therapeutic Perspectives.
New
In Pharmacol Ther, 06 Mar 2013
Spleen Tyrosine Kinase (SYK) and Bruton's Tyrosine Kinase (BTK) are non-receptor cytoplasmic tyrosine kinases that are primarily expressed in cells of hematopoietic lineage.
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
New
Impact
Stanford, United States. In J Clin Oncol, Feb 2013
OBJECTIVE: Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a critical signaling kinase in this pathway.
Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
Review
New
Parma, Italy. In Biochem Pharmacol, Jan 2013
Different irreversible tyrosin kinase inhibitors directed against epidermal growth factor receptor (EGFR), Bruton's tyrosine kinase (BTK), vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor tyrosine kinase (FGFR) have been developed and some of them have been employed clinically as anticancer agents.
X-linked agammaglobulinemia presenting with secondary hemophagocytic syndrome: a case report.
New
İzmir, Turkey. In Case Report Med, Dec 2012
Bruton tyrosine kinase (BTK) gene mutation was present (c.1581_1584delTTTG).
Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting.
Review
New
Heidelberg, Germany. In Ann Hematol, Nov 2012
Emerging strategies include mammalian target of rapamycin (mTOR) inhibitors, proteasome inhibitors, immune modulatory drugs, Bruton's tyrosine kinase inhibitors and others, all based on the dysregulated control of cell cycle machinery and impairment of several apoptotic pathways.
B-cell receptor pathobiology and targeting in NHL.
Review
New
Nashville, United States. In Curr Oncol Rep, Oct 2012
With the tremendous insight gained in the last 2 decades from basic science research, our understanding of the pathobiology of the B-cell receptor is leading to the discovery and clinical development of many new therapeutic targets such as Syk, Bruton's tyrosine kinase, and phosphatidylinositol 3-kinase.
Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.
Review
New
Stockholm, Sweden. In Curr Hematol Malig Rep, Sep 2012
Other new targeted agents, such as inhibitors of BTK and PI3Kdelta, have also been promising in FL.
The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.
Review
New
Madison, United States. In Curr Hematol Malig Rep, Sep 2012
Among the kinases which have been targeted are Spleen tyrosine kinase (Syk), the Bruton's tyrosine kinase (BTK), and phosphoinositide 3-kinase (PI3K).
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
New
Impact
Bethesda, United States. In Cancer Cell, Jul 2012
Blockade of B cell receptor signaling using the BTK inhibitor ibrutinib also downregulates IRF4 and consequently synergizes with lenalidomide in killing ABC DLBCLs, suggesting attractive therapeutic strategies.
The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils.
New
Impact
Tokyo, Japan. In Nat Immunol, Apr 2012
In the absence of Btk, the adaptor Mal was associated with PI(3)K and PTKs at the plasma membrane, whereas in control resting neutrophils, Btk interacted with and confined Mal in the cytoplasm.
The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.
New
Impact
Boston, United States. In J Clin Oncol, Mar 2012
Moreover, agents targeting bone biology (eg, zoledronic acid, anti-DKK-1 MoAb, anti-B-cell activating factor MoAb and bortezomib, Btk inhibitor) show promise not only in preserving bone integrity but also against MM.
A novel role for Bruton's tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells.
GeneRIF
Chandīgarh, India. In J Biol Chem, 2011
a novel role for Btk in HGF-induced DC inhibition.
BTK gene mutation in two non-identical twins with X-linked agammaglobulinemia associated with polyarticular juvenile idiopathic arthritis.
GeneRIF
Debrecen, Hungary. In Isr Med Assoc J, 2011
X-linked agammaglobulinemia is caused by mutations in the gene encoding Bruton tyrosine kinase.
Clinical manifestations and BTK gene defect in 4 unrelated Taiwanese families with Bruton's disease.
GeneRIF
Taipei, Taiwan. In Asian Pac J Allergy Immunol, 2011
We screened 52 members of 4 unrelated Taiwanese families with the BTK gene defect for BTK gene mutation and found that there were 6 symptomatic living patients with a confirmed defect.
Btk is a positive regulator in the TREM-1/DAP12 signaling pathway.
GeneRIF
Heidelberg, Germany. In Blood, 2011
our data identify Btk as a positive regulator in the ITAM-mediated TREM-1/DAP12 pathway and suggest its implication in inflammatory processes.
Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages.
GeneRIF
Gießen, Germany. In J Immunol, 2011
The Btk gene, which is mutated in human immunodeficiency X-linked agammaglobulinemia, is involved in upregulation of heme oxygenase-1 gene expression via Toll-like receptor (TLR) signaling in mouse alveolar macrophages.
Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk.
Impact
Shanghai, China. In Nat Immunol, 2011
Intracellular MHC class II molecules interacted with the tyrosine kinase Btk via the costimulatory molecule CD40 and maintained Btk activation, but cell surface MHC class II molecules did not.
